Literature DB >> 9570975

Immunohistochemical expression of thymidine phosphorylase in human endometrial cancer.

R Fujiwaki1, K Hata, K Iida, M Koike, K Miyazaki.   

Abstract

OBJECTIVE: To investigate correlations between the expression of thymidine phosphorylase (TP) by endometrial cancer cells and the density of microvessels within the tumor, the clinicopathologic features, and the prognosis.
METHODS: We examined tumor specimens obtained from 46 patients with endometrial cancer (9 FIGO stage IA, 16 stage IB, 8 stage IC, 1 stage IIA, 6 stage IIB, and 6 stage IIIC). The cellular expression of TP and the intratumoral density of microvessels were determined by immunohistochemistry using monoclonal antibodies to TP and factor VIII-related antigen, respectively. We investigated the relationship between the cellular expression of TP and the following factors: clinicopathologic features (menopausal status, histologic type, tumor size, histologic grade, myometrial invasion, cervical invasion, and metastasis), the microvessel count, and the disease-free survival period.
RESULTS: Of the 46 tumors, 19 (41%) were TP-positive. The microvessel count was significantly higher in TP-positive tumors than in TP-negative tumors (P = 0.01, Mann-Whitney U test). There was no significant correlation between TP expression and clinicopathologic features, and there was no significant difference in the disease-free survival period between patients with TP-positive tumors and patients with TP-negative tumors.
CONCLUSION: TP expression was not correlated with clinicopathologic features or prognosis, but was associated with an increased density of microvessels in endometrial cancer. These findings suggest that TP may play an important role in angiogenesis and may be involved in the tumorigenesis of endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9570975     DOI: 10.1006/gyno.1997.4929

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Thymidine phosphorylase expression in progression of cervical cancer: correlation with microvessel count, proliferating cell nuclear antigen, and apoptosis.

Authors:  R Fujiwaki; K Hata; K Iida; Y Maede; M Koike; K Miyazaki
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

2.  Expression of cyclooxygenase-2 and inducible nitric oxide synthase correlates with tumor angiogenesis in endometrial carcinoma.

Authors:  Wei Li; Ru-jun Xu; Li-hui Jiang; Jingfeng Shi; Xiang Long; Bei Fan
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

3.  Dihydropyrimidine dehydrogenase in normal and malignant endometrium: relationship with cell proliferation and thymidine phosphorylase.

Authors:  Ritsuto Fujiwaki; Kohji Iida; Kentaro Nakayama; Haruhiko Kanasaki; Tomoya Ozaki; Kohkichi Hata; Eiichi Sakai; Kohji Miyazaki
Journal:  Virchows Arch       Date:  2003-08-09       Impact factor: 4.064

4.  Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging in patients with rectal cancer: correlation with microvascular density and vascular endothelial growth factor expression.

Authors:  Yeo-Eun Kim; Joon Seok Lim; Junjeong Choi; Daehong Kim; Sungmin Myoung; Myeong-Jin Kim; Ki Whang Kim
Journal:  Korean J Radiol       Date:  2013-11-05       Impact factor: 3.500

5.  Tamoxifen induction of angiogenic factor expression in endometrium.

Authors:  S Hague; S Manek; M K Oehler; I Z MacKenzie; R Bicknell; M C P Rees
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

Review 6.  The dual role of thymidine phosphorylase in cancer development and chemotherapy.

Authors:  Annelies Bronckaers; Federico Gago; Jan Balzarini; Sandra Liekens
Journal:  Med Res Rev       Date:  2009-11       Impact factor: 12.944

7.  The cytosol activity of thymidine phosphorylase in endometrial cancer.

Authors:  Elzbieta Miszczak-Zaborska; Robert Kubiak; Andrzej Bieńkiewicz; Jacek Bartkowiak
Journal:  J Exp Clin Cancer Res       Date:  2008-11-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.